Ovarian hyperstimulation syndrome – it's time to reverse the trend
By Geeta Nargund,
BioNews
| 12. 05. 2016
Appeared in BioNews 880
Severe ovarian hyperstimulation syndrome (OHSS) is a serious and potentially fatal condition caused by overstimulation of the ovaries by drugs during IVF treatment. It is preventable with the modern management of IVF cycles, and the incidence of the condition should therefore be falling precipitously to almost zero – as it is in many countries. Indeed, my own clinic has not had a case of severe OHSS for over 15 years. However, in its latest report on adverse incidents in fertility clinics, the Human Fertilisation and Embryology Authority (HFEA) noted a 'slight increase' in the number of severe OHSS incidents reported to it in 2015 (1). In fact, this statement obfuscates the significance of the matter – there has been a 40 percent rise in hospital admissions with severe OHSS in UK fertility clinics in 2015 (2). This is an extraordinary statistic. The HFEA should be putting this alarming statistic on the front page and discussing methods to reverse this trend. Yet the very opposite appears to be the case. It is impossible to extract the number of OHSS...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Lucy Tu, The Guardian | 11.05.2025
Beth Schafer lay in a hospital bed, bracing for the birth of her son. The first contractions rippled through her body before she felt remotely ready. She knew, with a mother’s pit-of-the-stomach intuition, that her baby was not ready either...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...